

Agape ATP Corp. (ATPC)

Nasdaq; healthcare; SIC 8000, Services-Health Services; CIK 0001713210

Agape ATP Corp. ATPC; healthcare	
Grade	B  second fifth of 371 graded peers percentile 27.8; sampling error 2.5 points; lower is stronger
Rank	104 of 371
Profitability	D/E  percentile 81.1
Solvency	A  percentile 8.8
Growth and financing	B  percentile 32.5
Reliability	0.83 AUC filers with \$12.5M to \$120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$12.5M to \$120M assets total assets \$24.6M
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	late filer not computable: short runway, distress, fortress balance sheet
Inputs computable	8 of 14
Graded from	filings received through Apr 13, 2026 179 days before the rescan; latest periodic filing 10-Q received Aug 14, 2026
Last close	\$2.10 2026-10-02; market equity \$2.1M
Price used in grade	None




B, the elk

second fifth of its sector; letters are fifths of the 371 graded peers

Share price, twelve months to the rescan

split-adjusted close; the letter is fixed at the rescan that set it



Rescans on file: E from Apr 21, 2025, B from Apr 21, 2026

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Apr 13, 2026

ATP Corporation, a Nevada corporation ("the Company") was incorporated under the laws of the State of Nevada on June 1, 2016. ATP Corporation operates through its subsidiaries, namely, Agape ATP Corporation ("AATP LB"), a company incorporated in Labuan, Malaysia, and Agape Superior Living Sdn. Bhd. ("ASL"), a company incorporated in Malaysia on August 8, 2003. LB is an

investment holding company with 100% equity interest in Agape ATP International Holding Limited ("AATP HK"), a company May 8, 2020, the Company entered into a Share Exchange Agreement with Mr.

The fourteen inputs


lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 81.1						
Gross profitability		3.4%	32.2%	87.3	372	2025-12-31
Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		1.0%	(6.6%)	82.5	811	2025-12-31
Gross margin stability, five years		5.7 pts	2.8 pts	73.6	243	2025-12-31
Solvency, sleeve percentile 8.8						
Twelve-month failure probability		not computable	0.07%			latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime		14.37	(0.31)	4.9	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		not computable	(4.51x)			one or more required annual facts are missing
Current ratio		11.82x	2.96x	12.6	839	2025-12-31
Growth and financing, sleeve percentile 32.5						
Revenue growth, three-year compound		(6.4%)	10.0%	82.4	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			four consecutive annual FCF observations are required; found 2
Reinvestment rate		not computable	37.1%			pretax income must exceed the validity floor and imply a 0%-100% tax rate
Asset growth, three years		106.5%	2.1%	1.8	704	2025-12-31
Net share issuance, one year		0.05%	2.5%	13.4	634	2026-03-17

Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Late filer	found 1 NT 10-K/Q filings in the last eight quarters



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
99	Sensus Healthcare, Inc. (SRTS)	26.5	B	
100	Lineage Cell Therapeutics, Inc. (LCTX)	26.8	B	
101	Traverse Therapeutics, Inc. (TVTX)	27.0	B	
102	Tela Bio, Inc. (TELA)	27.3	B	fortress balance sheet
103	Alphatec Holdings, Inc. (ATEC)	27.6	B	
104	Agape ATP Corp. (ATPC) <	27.8	B	late filer
105	Agios Pharmaceuticals, Inc. (AGIO)	28.1	B	short runway
106	Myriad Genetics Inc. (MYGN)	28.4	B	fortress balance sheet
107	DocGo Inc. (DCGO)	28.6	B	late filer, fortress balance sheet
108	Healthcare Services Group Inc. (HCSG)	28.9	B	
109	Staar Surgical Co. (STAA)	29.2	B	

What the price implies

at the 2026-10-02 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(96.3%)	8.0%	0
Distance from 52-week high	(96.9%)	(31.4%)	1
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	(40.2%)	(1.0%)	14
Book value to price	10.44	0.28	100
Sales to price	0.72	0.31	76
Composite equity issuance, five years	not computable	20.3%	
Relative strength against the sector, log excess return	(3.50)	(0.14)	0

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	fail
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass

Cash, filings, liquidity	
Cash and equivalents	\$45,480
Operating cash flow, four quarters	-\$970,178
Months of runway	not finite
Days since last periodic filing	56 (10-Q received Aug 14, 2026)
Median daily dollar volume, 63 sessions	\$56,333

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$838,270	2025-12-31	2026-04-13	10-K	0001493152-26-016297
2	assets	us-gaap:Assets	\$24.6M	2025-12-31	2026-04-13	10-K	0001493152-26-016297
3	net income	us-gaap:NetIncomeLoss	-\$2.3M	2025-12-31	2026-04-13	10-K	0001493152-26-016297
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$2.4M	2025-12-31	2026-04-13	10-K	0001493152-26-016297
5	assets	us-gaap:Assets	\$3.2M	2024-12-31	2026-04-13	10-K	0001493152-26-016297
6	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$1.5M	2025-12-31	2026-04-13	10-K	0001493152-26-016297
7	gross profit	us-gaap:GrossProfit	\$759,148	2024-12-31	2026-04-13	10-K	0001493152-26-016297
8	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$1.3M	2024-12-31	2026-04-13	10-K	0001493152-26-016297
9	gross profit	us-gaap:GrossProfit	\$936,572	2023-12-31	2025-03-31	10-K	0001641172-25-001611
10	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$1.4M	2023-12-31	2025-03-31	10-K	0001641172-25-001611
11	gross profit	us-gaap:GrossProfit	\$1.2M	2022-12-31	2024-04-01	10-K	0001493152-24-012467
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$1.9M	2022-12-31	2024-04-01	10-K	0001493152-24-012467
13	gross profit	us-gaap:GrossProfit	\$719,629	2021-12-31	2023-03-31	10-K	0001493152-23-010029
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$1.0M	2021-12-31	2023-03-31	10-K	0001493152-23-010029
15	current assets	us-gaap:AssetsCurrent	\$24.3M	2025-12-31	2026-04-13	10-K	0001493152-26-016297
16	current liabilities	us-gaap:LiabilitiesCurrent	\$2.1M	2025-12-31	2026-04-13	10-K	0001493152-26-016297
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$11.8M	2025-12-31	2026-04-13	10-K	0001493152-26-016297
18	operating income	us-gaap:OperatingIncomeLoss	-\$3.3M	2025-12-31	2026-04-13	10-K	0001493152-26-016297
19	book equity	us-gaap:StockholdersEquity	\$22.5M	2025-12-31	2026-04-13	10-K	0001493152-26-016297
20	liabilities	us-gaap:Liabilities	\$2.2M	2025-12-31	2026-04-13	10-K	0001493152-26-016297
21	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$3,959	2021-12-31	2022-07-05	10-K/A	0001493152-22-018503
22	depreciation amortization	us-gaap:Depreciation	\$75,797	2021-12-31	2023-03-31	10-K	0001493152-23-010029
23	operating income	us-gaap:OperatingIncomeLoss	-\$1.9M	2021-12-31	2023-03-31	10-K	0001493152-23-010029
24	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsDeductibleItems	\$137,067	2021-12-31	2023-03-31	10-K	0001493152-23-010029
25	income tax	us-gaap:IncomeTaxExpenseBenefit	\$137,067	2021-12-31	2023-03-31	10-K	0001493152-23-010029
26	current assets	us-gaap:AssetsCurrent	\$3.9M	2021-12-31	2023-03-31	10-K	0001493152-23-010029
27	current liabilities	us-gaap:LiabilitiesCurrent	\$1.3M	2021-12-31	2023-03-31	10-K	0001493152-23-010029
28	current assets	us-gaap:AssetsCurrent	\$5.7M	2020-12-31	2022-07-05	10-K/A	0001493152-22-018503
29	current liabilities	us-gaap:LiabilitiesCurrent	\$1.0M	2020-12-31	2022-07-05	10-K/A	0001493152-22-018503
30	assets	us-gaap:Assets	\$5.7M	2023-12-31	2025-03-31	10-K	0001641172-25-001611
31	assets	us-gaap:Assets	\$2.8M	2022-12-31	2024-04-01	10-K	0001493152-24-012467
32	shares outstanding	dei:EntityCommonStockSharesOutstanding	1,000,626	2026-03-17	2026-04-13	10-K	0001493152-26-016297
33	shares outstanding	dei:EntityCommonStockSharesOutstanding	50,005,381	2025-03-28	2025-03-31	10-K	0001641172-25-001611